Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Delsym is a prominent brand of over-the-counter cough suppressants, recognized for its patented 12-hour extended-release formula. The brand's core technology involves dextromethorphan polistirex, a sulfonated styrene-divinylbenzene copolymer complex that allows for sustained drug release. Delsym was originally introduced by Pennwalt and was later a flagship product of Adams Respiratory Therapeutics before being acquired by Reckitt in 2008. Today, the brand encompasses a wide range of cough and cold products for both adult and pediatric use, maintaining a significant market share in the respiratory health sector. Its product portfolio includes liquid suspensions, lozenges, and multi-symptom formulations targeting cough, sore throat, and chest congestion. Delsym is widely distributed through major retail pharmacies and grocery chains across North America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Delsym.